Enhanced hepatocarcinogenesis in mouse models and human hepatocellular carcinoma by coordinate KLF6 depletion and increased messenger RNA splicing

Hepatology

Volumn 56, Issue 4, 2012, Pages 1361-1370

  Vetter, Diana ^a,b   Cohen Naftaly, Michal ^a   Villanueva, Augusto ^c   Lee, Youngmin A ^a   Kocabayoglu, Peri ^a   Hannivoort, Rebekka ^a,d   Narla, Goutham ^a   M Llovet, Josep ^a,c,e   Thung, Swan N ^a   Friedman, Scott L ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; DIETHYLNITROSAMINE; KRUPPEL LIKE FACTOR 6; MESSENGER RNA; PROTEIN; SPLICE VARIANT 1 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DNA SYNTHESIS; GENETIC TRANSDUCTION; HEPATITIS C; HUMAN; IMMUNOPRECIPITATION; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PLOIDY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; RNA SPLICING; TUMOR VOLUME;

ANALYSIS OF VARIANCE; ANIMALS; CARCINOMA, HEPATOCELLULAR; DIETHYLNITROSAMINE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPACIVIRUS; HEPATITIS B VIRUS; HEPATOCYTES; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; LIVER NEOPLASMS; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, TRANSGENIC; MUTATION; NERVE TISSUE PROTEINS; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS; RANDOM ALLOCATION; REFERENCE VALUES; RNA SPLICING; STATISTICS, NONPARAMETRIC; TUMOR CELLS, CULTURED;

EID: 84867193519     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25810     Document Type: Article

References (30)

1. Hoshida Y, Toffanin S, Lachenmayer A, Villanueva A, Minguez B, Llovet JM. Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis 2010; 30: 35-51.
2. Tarocchi M, Hannivoort R, Hoshida Y, Lee UE, Vetter D, Narla G, et al. Carcinogen-induced hepatic tumors in KLF6+/- mice recapitulate aggressive human hepatocellular carcinoma associated with p53 pathway deregulation. HEPATOLOGY 2011; 54: 522-531.
3. Pearson R, Fleetwood J, Eaton S, Crossley M, Bao S. Kruppel-like transcription factors: a functional family. Int J Biochem Cell Biol 2008; 40: 1996-2001.
4. Narla G, Friedman SL. Kruppel like factors and the liver. In: Nagai R, Friedman SL, Kasuga M, eds. The Biology of Kruppel-like Factors. Vol. 1. New York: Springer; 2009: 141-150.
5. Narla G, Heath KE, Reeves HL, Li D, Giono LE, Kimmelman AC, et al. KLF6, a candidate tumor suppressor gene mutated in prostate cancer. Science 2001; 294: 2563-2566.
6. DiFeo A, Narla G, Camacho-Vanegas O, Nishio H, Rose SL, Buller RE, et al. E-cadherin is a novel transcriptional target of the KLF6 tumor suppressor. Oncogene 2006; 25: 6026-6031.
7. Slavin DA, Koritschoner NP, Prieto CC, Lopez-Diaz FJ, Chatton B, Bocco JL. A new role for the Kruppel-like transcription factor KLF6 as an inhibitor of c-Jun proto-oncoprotein function. Oncogene 2004; 23: 8196-8205.
8. Ito G, Uchiyama M, Kondo M, Mori S, Usami N, Maeda O, et al. Kruppel-like factor 6 is frequently down-regulated and induces apoptosis in non-small cell lung cancer cells. Cancer Res 2004; 64: 3838-3843.
9. DiFeo A, Narla G, Hirshfeld J, Camacho-Vanegas O, Narla J, Rose SL, et al. Roles of KLF6 and KLF6-SV1 in ovarian cancer progression and intraperitoneal dissemination. Clin Cancer Res 2006; 12: 3730-3739.
10. Kremer-Tal S, Narla G, Chen Y, Hod E, DiFeo A, Yea S, et al. Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. J Hepatol 2007; 46: 645-654.
11. Kremer-Tal S, Reeves HL, Narla G, Thung SN, Schwartz M, Difeo A, et al. Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. HEPATOLOGY 2004; 40: 1047-1052.
12. Song J, Kim CJ, Cho YG, Kim SY, Nam SW, Lee SH, et al. Genetic and epigenetic alterations of the KLF6 gene in hepatocellular carcinoma. J Gastroenterol Hepatol 2006; 21: 1286-1289.
13. Cho YG, Kim CJ, Park CH, Yang YM, Kim SY, Nam SW, et al. Genetic alterations of the KLF6 gene in gastric cancer. Oncogene 2005; 24: 4588-4590.
14. Reeves HL, Narla G, Ogunbiyi O, Haq AI, Katz A, Benzeno S, et al. Kruppel-like factor 6 (KLF6) is a tumor-suppressor gene frequently inactivated in colorectal cancer. Gastroenterology 2004; 126: 1090-1103.
15. Hirasawa Y, Arai M, Imazeki F, Tada M, Mikata R, Fukai K, et al. Methylation status of genes upregulated by demethylating agent 5-aza-2′-deoxycytidine in hepatocellular carcinoma. Oncology 2006; 71: 77-85.
16. Yea S, Narla G, Zhao X, Garg R, Tal-Kremer S, Hod E, et al. Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma. Gastroenterology 2008; 134: 1521-1531.
17. Narla G, DiFeo A, Fernandez Y, Dhanasekaran S, Huang F, Sangodkar J, et al. KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis. J Clin Invest 2008; 118: 2711-2721.
18. Chen H, Chen L, Sun L, Zhen H, Li X, Zhang Q. A small interfering RNA targeting the KLF6 splice variant, KLF6-SV1, as gene therapy for gastric cancer. Gastric Cancer 2011; 14: 339-352.
19. Hartel M, Narla G, Wente MN, Giese NA, Martignoni ME, Martignetti JA, et al. Increased alternative splicing of the KLF6 tumour suppressor gene correlates with prognosis and tumour grade in patients with pancreatic cancer. Eur J Cancer 2008; 44: 1895-1903.
20. Difeo A, Huang F, Sangodkar J, Terzo EA, Leake D, Narla G, et al. KLF6-SV1 is a novel antiapoptotic protein that targets the BH3-only protein NOXA for degradation and whose inhibition extends survival in an ovarian cancer model. Cancer Res 2009; 69: 4733-4741.
21. DiFeo A, Feld L, Rodriguez E, Wang C, Beer DG, Martignetti JA, et al. A functional role for KLF6-SV1 in lung adenocarcinoma prognosis and chemotherapy response. Cancer Res 2008; 68: 965-970.
22. Rodriguez E, Aburjania N, Priedigkeit NM, DiFeo A, Martignetti JA. Nucleo-cytoplasmic localization domains regulate Kruppel-like factor 6 (KLF6) protein stability and tumor suppressor function. PLoS One 2010; 5.
23. Bechmann LP, Gastaldelli A, Vetter D, Patman GL, Pascoe L, Hannivoort RA, et al. Glucokinase links Kruppel-like factor 6 to the regulation of hepatic insulin sensitivity in non-alcoholic fatty liver disease. HEPATOLOGY 2012; 55: 1083-1093.
24. Leow CC, Wang BE, Ross J, Chan SM, Zha J, Carano RA, et al. Prostate-specific Klf6 inactivation impairs anterior prostate branching morphogenesis through increased activation of the Shh pathway. J Biol Chem 2009; 284: 21057-21065.
25. Narla G, Kremer-Tal S, Matsumoto N, Zhao X, Yao S, Kelley K, et al. In vivo regulation of p21 by the Kruppel-like factor 6 tumor-suppressor gene in mouse liver and human hepatocellular carcinoma. Oncogene 2007; 26: 4428-4434.
26. Narla G, Difeo A, Reeves HL, Schaid DJ, Hirshfeld J, Hod E, et al. A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. Cancer Res 2005; 65: 1213-1222.
27. Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RM, Gerald WL. Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest 2004; 113: 913-923.
28. Sangodkar J, DiFeo A, Feld L, Bromberg R, Schwartz R, Huang F, et al. Targeted reduction of KLF6-SV1 restores chemotherapy sensitivity in resistant lung adenocarcinoma. Lung Cancer 2009; 66: 292-297.
29. Ghosh A, Stewart D, Matlashewski G. Regulation of human p53 activity and cell localization by alternative splicing. Mol Cell Biol 2004; 24: 7987-7997.
30. Berge EO, Staalesen V, Straume AH, Lillehaug JR, Lonning PE. Chk2 splice variants express a dominant-negative effect on the wild-type Chk2 kinase activity. Biochim Biophys Acta 2010; 1803: 386-395.